GeoVax Labs, Inc.GOVX

GeoVax Labs, Inc. is a biotechnology company with a balance sheet that looks like it has been left in the rain: $1.3m of cash, $2.5m of liabilities, and a stockholders’ equity figure of $493,770 at 31 March 2026. The 10-Q for that quarter reports a net loss of $5.3m, an operating loss of $5.3m, and no revenue to offset the spend. In plain terms, the company is haemorrhaging cash faster than it can replenish it. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/832489/000143774926021319/xslF345X06/rdgdoc.xml)

GeoVax’s public story is built around two technology platforms: MVA-based vaccines for infectious diseases and a tumour-debulking approach called Gedeptin for oncology. The company’s own product pages and pipeline summaries list programmes in Ebola, Marburg, MERS, and several cancer targets, but the 10-Q shows no revenue, no operating income, and no cash receipts from customers. The mismatch between the slide-deck narrative and the filing reality is the only thing that is growing. (source: Technology, https://www.geovax.com/technology; Pipeline Summary, https://www.geovax.com/technology-pipeline/pipeline-summary; 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/832489/000143774926021319/xslF345X06/rdgdoc.xml)

The company’s research and development expense for the quarter was $3.9m, which is the single largest cash outflow in the filing, and the net cash used in operating activities was $3.5m. Capital expenditure was zero-the company is not building factories or buying equipment, just burning cash on R&D and overheads. The 10-Q also shows no debt repayments, no share buybacks, and no new financing in the quarter. Equity has been compressed to less than half a million dollars, which is a figure more often seen in early-stage start-ups than in a listed biotech. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/832489/000143774926021319/xslF345X06/rdgdoc.xml)

The 8-K filed on 10 July 2026 is a regulatory compliance document, not a rescue plan. It sets out board committee charters and governance matters, but it does not disclose any new funding, debt facility, equity issuance, or asset sale that would materially change the company’s liquidity profile. The filing is a reminder that the board’s current priority appears to be governance theatre rather than financial rescue. (source: 8-K (2026-07-10), https://www.sec.gov/Archives/edgar/data/832489/000143774926023320/govx20260709_8k.htm)

The SEC EDGAR index for GeoVax lists the usual filings-Forms 10-Q, 8-K, and a set of XBRL exhibits-but none of them contain revenue, customer names, contract values, or clinical trial milestones that would translate into cash. The company’s product pages show candidate vaccines and mechanisms, yet the filings contain no evidence of sales, approvals, or partnerships that would validate the platform story. Until the company can show a single dollar of revenue or a signed supply agreement, the gap between narrative and numbers remains unbridgeable. (source: SEC EDGAR filing index for CIK 832489, https://www.sec.gov/edgar/browse/?CIK=832489)

If investors are looking for chart context, the evidence supplied does not include a TradingView route or price series. The file therefore stops at the company-level facts: GeoVax is a cash-burning, pre-revenue biotech with no operating income, no debt facilities disclosed, and equity reduced to under half a million dollars. The only market mechanics on display are the ones the company itself controls: R&D spend, cash burn, and board oversight. (source: SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0000832489.json)